Phase 1–related adverse events by grade
| Adverse event . | Cohort 1 (n = 6) . | Cohort 2 (n = 7) . | Total (n = 13) . | |||
|---|---|---|---|---|---|---|
| % . | Grade 3/4, % . | % . | Grade3/4, % . | % . | Grade 3/4, % . | |
| Diarrhea | 83 | 17 | 71 | 0 | 77 | 8 |
| Fatigue | 33 | 0 | 43 | 14 | 39 | 8 |
| Leukopenia | 50 | 33 | 14 | 14 | 31 | 23 |
| Hypertension | 0 | 0 | 57 | 0 | 31 | 0 |
| Neutropenia | 33 | 33 | 14 | 14 | 23 | 23 |
| Anemia | 50 | 50 | 0 | 0 | 23 | 23 |
| Asthenia | 17 | 17 | 14 | 0 | 15 | 8 |
| Nausea | 0 | 0 | 29 | 0 | 15 | 0 |
| Dyspepsia | 0 | 0 | 29 | 0 | 15 | 0 |
| Thrombocytopenia | 17 | 0 | 14 | 0 | 15 | 0 |
| Headache | 0 | 0 | 29 | 0 | 15 | 0 |
| Adverse event . | Cohort 1 (n = 6) . | Cohort 2 (n = 7) . | Total (n = 13) . | |||
|---|---|---|---|---|---|---|
| % . | Grade 3/4, % . | % . | Grade3/4, % . | % . | Grade 3/4, % . | |
| Diarrhea | 83 | 17 | 71 | 0 | 77 | 8 |
| Fatigue | 33 | 0 | 43 | 14 | 39 | 8 |
| Leukopenia | 50 | 33 | 14 | 14 | 31 | 23 |
| Hypertension | 0 | 0 | 57 | 0 | 31 | 0 |
| Neutropenia | 33 | 33 | 14 | 14 | 23 | 23 |
| Anemia | 50 | 50 | 0 | 0 | 23 | 23 |
| Asthenia | 17 | 17 | 14 | 0 | 15 | 8 |
| Nausea | 0 | 0 | 29 | 0 | 15 | 0 |
| Dyspepsia | 0 | 0 | 29 | 0 | 15 | 0 |
| Thrombocytopenia | 17 | 0 | 14 | 0 | 15 | 0 |
| Headache | 0 | 0 | 29 | 0 | 15 | 0 |